Abstract The molecular imaging techniques allow monitoring of the transplanted cells in the same individuals over time, from early localization to the survival, migration, and differentiation. Generally, there are two methods of stem cell labeling: direct and indirect labeling methods. The direct labeling method introduces a labeling agent into the cell, which is stably incorporated or attached to the cells prior to transplantation. Direct labeling of cells with radionuclides is a simple method with relatively fewer adverse events related to genetic responses. However, it can only allow short-term distribution of transplanted cells because of the decreasing imaging signal with radiodecay, according to the physical half-lives, or the signal becomes more diffuse with cell division and dispersion. The indirect labeling method is based on the expression of a reporter gene transduced into the cell before transplantation, which is then visualized upon the injection of an appropriate probe or substrate. In this review, various imaging strategies to monitor the survival and behavior change of transplanted stem cells are covered. Taking these new approaches together, the direct and indirect labeling methods may provide new insights on the roles of in vivo stem cell monitoring, from bench to bedside.
Introduction
Stem cell therapy applies stem cells to injured tissue to treat disease or injury. Stem cells have the ability to regenerate and differentiate, and they can potentially replace diseased or damaged cells. The current therapy for acute myocardial infarction (MI) is based on stem cells, presenting a significant advancement over many traditional approaches to disease treatment [1] [2] [3] . Experimental and clinical studies of stem cell transplantation in the heart revealed that stem cells can differentiate into cardiac myocytes, endothelial cells, and secrete paracrine factors that can reduce myocyte death, improve the microcirculation, attenuate adverse remodeling, and boost the regenerative capacity of MI. Stem cells can be isolated from various sources including bone marrow, skin, amniotic fluid, and adipose tissue [4] [5] [6] [7] [8] . The main goal of stem cell therapy is to repopulate the damaged tissue with functional cells. Over the last decade, progress in molecular imaging has allowed the investigators to answer some of these unsolved problems by providing a deep understanding of stem cell behavior in a living body [9, 10] . Particularly, some of the imaging strategies have the potential to be translated to patients, which makes them appropriate for use in clinical trials [11] . In vivo cell-tracking methods are able to monitor noninvasively and in real time at the injected site and to allow observation of the distribution and viability of the therapeutically administered cells. There are two main classes of cell labeling methods for molecular imaging: the direct and indirect labeling methods. For in vivo visualization, transplanted cells need to be directly labeled ex vivo with radiotracers [12] [13] [14] [15] [16] [17] [18] , nanoparticles, or quantum dots [19] [20] [21] [22] , or they have to express a reporter gene by indirect labeling [23, 24] . Direct labeling was performed prior to cell transplantation  with  99m Tc-hexamethylpropylenamine oxime (  99m Tc-HMPAO) or   111 In-oxine [25] . It has been used in conjunction with single-photon emission computed tomography (SPECT), superparamagnetic iron oxide particles (SPIO) for magnetic resonance imaging (MRI), 6 4 Cupyruvaldehyde-bis(N4-methylthiosemicarbazone ( 64 Cu-PTSM) [26] , and 2-18 F-fluoro-2-deoxy-D-glucose ( 18 F-FDG) [27] with positron emission tomography (PET) for tracking various cell types following transplantation. Indirect labeling for nuclear medicine, including the herpes simplex virus type 1 thymidine kinase (HSV1-tk) [23] or human sodium iodide symporter (hNIS) [24] , has been used for cell tracking in the heart. Direct and indirect labeling methods are powerful tools for molecular imaging, and they have advantages and disadvantages. Therefore, each labeling modality should be used properly according to their purposes.
Items Desired for Ideal Stem Cell Imaging Modalities
The ideal imaging agent/modality should provide the realtime visualization of distribution over time, quantification of viable transplanted stem cells, and long-term quantification of transplanted stem cell survival. Also, the applied labeling modality should not disturb the normal functions of stem cells.
The biocompatibility, toxicity, and safety should be considered seriously not only for the stem cells, but also for the stem cell recipient individuals, and they should be considered when choosing which modality to use for imaging. All imaging modalities have a certain degree of background/nonspecific signal, which may be confused with the signal interpretation under study. The preferred imaging modality should be able to provide a good contrast between the target and background signal by achieving a large signal-to-noise ratio. Additionally, it should have good specificity. Table 1 introduces different imaging modalities for the assessment of delivery and shortand long-term monitoring of stem cell viability and biology.
Direct Labeling
One of the most commonly used methods for the labeling of stem cells in molecular imaging is direct labeling [28] [29] [30] [31] . In a direct labeling strategy, labeling agents are introduced into the cells prior to transplantation. Depending on the imaging modality to be used, stem cells can be labeled with radionuclides for SPECT or PET [32] [33] [34] [35] and SPIO for MRI (Fig. 1) [36, 37] . Direct cell labeling is fairly simple and does not involve genetic modification of the cell. For example, cells are actively labeled with the appropriate method in vitro and are administered to a recipient. One disadvantage of direct cell labeling methods is that the label is diluted when cells divide, resulting in decreased amounts of labeled agent per individual cell. Furthermore, the label can be distributed asymmetrically to the progeny cells according to cell division or can be lost by the cells. These factors act as a limitation for long-term imaging. Additionally, iron-based agents for MRI require long incubation periods for cell labeling and are not suitable for patients with an intracardiac defibrillators or pacemakers. PET and SPECT imaging using a radionuclide has the high sensitivity and spatial resolution. Therefore, it can provide dynamic tracking imaging and the tissue distribution of transplanted stem cells injected as a therapeutic agent. Direct labeling agents for cell tracking have been developed for in vivo imaging [38, 39] In-oxine are nonspecific cell-labeling agents and are retained in cells by penetration through the cell membrane [43] . Hexadecyl-4- I-HIB-labeled ADSCs was possible for 9 and 3 days in the normal and MI model, respectively, which was feasible only by an indirect labeling method previously using the reporter gene [29, 30] (Fig. 2) . They showed that the radioactivity of the transplanted 124 I-HIB-labeled ADSCs remained at 24.67 ± 1.18 % of the day 1 value (100 %) (P<0.05) 9 days after transplantation in the normal myocardium (Fig. 2) . However, in the MI, the radioactivity of the transplanted 124 I-HIB-labeled ADSCs remained at 13.62± 7.66 % of the 0.08 day (2 h) value (100 %) (P<0.05) 3 days after transplantation (Fig. 2) . This difference of in vivo monitoring periods reflects the poor viability of transplanted ADSCs in host tissue due to harsh microenvironments such as ischemia, inflammation, and/or anoikis in the infarcted myocardium [44] . Tc-HMPAO, or SPIO) or anchored to the cell membrane (b, e.g., 64 Cu-DOTA-HB, 123/124 I-HIB). To track the transplanted stem cells, first, the direct-labeled stem cells are transplanted to the target tissue/ organ. Then, noninvasive imaging including MRI or radionuclide imaging using PET or SPECT is performed at the target site for detection of transplanted stem cells [14, 45] . 64 Cu can react with a wide variety of chelator systems including 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-triacetic acid because of its wellestablished coordination chemistry [46, 47] . DOTA is currently used in 64 Cu-diacetyl-bis(N4-methylthiosemicarbazone ( 64 Cu-ATSM), approved by the US Food and Drug Administration (FDA) in the USA. Therefore, the DOTA chelator is better clinically available and has a simple synthetic process [48] . 64 Cu can potentially be linked to the target, including peptides, antibodies, or nanoparticles, via a specified chelator system. Hexadecyl benzoate (HB) has a lipophilic property, so it easily and tightly anchors with the cell membrane, similar to HIB. Moreover, it is free from an effect mediated by other receptors existing in the cell. Kim et al. reported that 64 Culabeled hexadecyl-1,4,7,10-tetraazacyclododecane-tetraacetic acid-benzoate ( 64 Cu-DOTA-HB)-labeled ADSCs were monitored for 18 h in normal rat heart by PET imaging (Fig. 3) . Adonai et al. reported that the lipophilic agent, 64 Cu-PTSM, was rapidly effluxed from C6 rat glioma cells; radioactivity was decreased by≈80 % at 24 h [14] . Also, Park et al. reported that the radioactivity of intravenously injected 64 Cu-PTSMlabeled K562 (human erythromyeloblastoid leukemia cell line) cells were rapidly decreased in the lungs from 2 h to 24 h [49] . However, the intramuscularly injected 64 Cu-DOTA-HB-labeled ADSCs were clearly visualized at the injected site for 18 h. These results indicate that HIB or HB can utilize promising radiotracers for monitoring of transplanted stem cells [50] . 
Indirect Labeling
There is an increasing need for the understanding of the posttransplantation behavior of stem cells. Reporter genes for imaging can precisely monitor stem cell behavior longitudinally, unlike direct labeling. Target cells can be genetically modified to be labeled by the introduction of a reporter gene. Reporter genebased imaging offers unique advantages of long-term imaging for cell survival and longitudinal measurements. Although indirect labeling using reporter genes has disadvantages including the cost, cellular dysfunction, cell death, immunogenicity of the gene product, and potential risk for uncontrolled growth or malignancy, the advanced development in molecular biology and imaging modalities has produced a reporter gene system that allows the evaluation of transgene expression in various diseases. From these advancements, various types of reporter genes or probe systems have developed. (Fig. 4) [19, [51] [52] [53] [54] [55] [56] [57] [58] [59] . Reporter genes consist of gene regulatory elements, such as promoters and enhancers, which drive the reporter gene DNA sequence and poly A sequence providing stabilization on the final product. Initially, reporter genes were mainly used in histology and ex-vivo studies (beta-galactosidase and luciferase) to assess the transgene expression in many different tissues and organs [60] [61] [62] . The reporter gene needs to include cells before transplantation for stem cell imaging. The incorporated reporter gene will be expressed only in the case that stem cells are viable. However, in the case of cell death, the signal of the reporter gene becomes extinct. The substrate can be externally administered at the interested point of imaging time, and the specific signal was expressed by the interaction between the substrate and encoded reporter protein. Through bioluminescence imaging or radionuclide imaging, the specific signal of the reporter gene can be detected noninvasively. The reporter gene was commonly used for monitoring survival in the transplanted stem cells with the reporter gene controlled by a cytomegalovirus (CMV) based on the constitutive promoter [63] . When the cell is viable and transcriptional machinery intact, it will result in the production of a reporter protein. Additionally, particular biological pathways can be investigated using the reporter gene.
NIS is an intrinsic membrane protein in thyroid cells with 13 transmembrane domains, which mediates the active transport of iodine into thyroid follicular cells (Fig. 5) . NIS genes can be used as imaging reporter genes in PET as well as SPECT imaging, because they concentrate radionuclides such as Tc-pertechnetate, which can be visualized by conventional γ-camera or PET [64] [65] [66] . Terrovitis et al. showed that NIS-expressing (NIS + ) rat cardiac-derived stem cells (rCDCs) were visualized in vivo up to 6 days post-injection in a rat MI model by SPECT [67] . Lee et al. showed that intramyocardially injected rats with NIS-expressing adenovirus-transfected canine stem cells (Ad-hNIS-canine ADSCs) were monitored for 9 days in the canine MI model by 99m Tc-pertechnetate ( 99m TcO4 − ) SPECT imaging (Fig. 6) [68] .
A specific promoter is used for the investigation of certain pathways, and the target reporter protein is made only when the intracellular signal is active for protein production. The activation of that specific promoter will drive the expression of the reporter gene, and this could be visualized noninvasively by using the proper imaging modalities. Kang et al. developed transgenic mice using NIS expression driven by the α-MHC promoter for cardiomyocyte-specific expression, in which NIS is constitutively expressed as an imaging reporter gene only in cardiomyocytes. They showed that the myocardium of transgenic mice showed rapid and intense uptake of 99m Tc-pertechnetate and also showed long retention by γ-camera imaging [24] . Kim et al. reported that bone marrow-derived mesenchymal stem cells (BMSCs) from transgenic mice [24] , using NIS expression driven by the α-MHC promoter, expressed upregulated NIS gene activity according to in vitro cardiomyogenic differentiation (Fig. 7) [69] . These results will likely lead to future 
Summary
In this review, transplanted stem cell survival and differentiation were monitored using direct and indirect labeling. Generally, direct imaging techniques only enable the short-term monitoring of stem cells because of the physical half-life of the labeled radionuclide.
However, in the current study, transplanted ADSCs were longitudinally monitored by PET in the normal and MI model using 124 I-HIB, which has a relatively long half-life, which reflects cell survival change against the harsh microenvironment of MI. Survival of transplanted stem cells was longitudinally monitored by using NIS reporter genes. Also, cardiomyogenic differentiation of stem cells in vitro was monitored using a tissue-specific promoter, an α-MHC promoterdriven NIS reporter gene. These new approaches including direct and indirect imaging may provide new insights into the roles of stem cell monitoring in the living body for stem cell therapy, from pre-clinical studies to clinical trials.
